Neoadjuvant Concurrent Radiotherapy and Chemotherapy in Early Breast Cancer Patients: Long-Term Results of a Prospective Phase II Trial

Abstract

Background: Neoadjuvant concurrent radiochemotherapy makes it possible to increase the breast conservation rate. This study reports the long term outcome of this treatment. Methods: From 2001 to 2003, 59 women with T2–3 N0–2 M0 invasive breast cancer (BC) not amenable to upfront breast conserving treatment (BCS) were included in this prospective, non-randomized phase II study. Chemotherapy (CT) consisted of four cycles of continuous 5-FU infusion and Vinorelbine. Starting concurrently with the second CT cycle, normofractionated RT was delivered to the breast and LN. Breast surgery was then performed. Results: Median follow-up (FU) was 13 years [3–18]. BCS was performed in 41 (69%) patients and mastectomy in 18 patients, with pathological complete response rate of 27%. Overall and distant-disease free survivals rates at 13 years were 70.9% [95% CI 59.6–84.2] and 71.5% [95% CI 60.5–84.5] respectively. Loco regional and local controls rates were 83.4% [95% CI 73.2–95.0] and 92.1% [95% CI 83.7–100], respectively. Late toxicity (CTCAE-V3) was assessed in 51 patients (86%) with a median follow-up of 13 years. Fifteen presented grade 2 fibrosis (29.4%), 8 (15.7%) had telangiectasia, and 1 had radiodermatitis. Conclusions: This combined treatment provided high long-term local control rates with limited side-effects.

The role of miRNAs as biomarkers in breast cancer

“…Nonetheless, survival rates have significantly increased due to the use of hormone treatment, radiation, and chemotherapy ( 86 ). Chemotherapy and radiotherapy are utilized as neoadjuvant treatments for metastatic breast cancer, prior to mastectomy or breast conservative surgery and axillary node clearance ( 87 ). Chemotherapy, radiation therapy, and hormone therapy are the main treatments for progressing disease (stage IV).…”

Effect of low temperature plasma on the transcriptome of breast cancer cells

“…Breast cancer is routinely classi ed based on lymph node status and distant metastasis, and includes expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2(HER2) [3]. Treatments for breast cancer are tumor-metastasized, and speci cally include breast-conserving surgery [4], chemoradiotherapy [5], or drug-adjuvant therapy [6]. The current meta-analysis indicated that breastconserving therapy had an increased risk of local recurrence [7].…”

Study on the Potential Mechanism of Traditional Marine Chinese Medicine Beishashen in Preventing Lung Injury Induced by Radiotherapy and Chemotherapy

“…Radiation therapy is an efective tool used in the treatment of tumors, but it can cause normal tissue damage, especially lung injury after radiotherapy for breast cancer, lung cancer, or other malignant tumors of the chest [2]. In addition, many patients undergo synchronous chemotherapy to enhance the antitumor efcacy of radiation, which can lead to the exacerbation of lung injury, known as chemotherapy-induced lung injury (CILI) [3,4]. With an incidence rate of 10% to 40%, radiation-induced lung injury (RILI) is the most frequent and harmful side efect of radiotherapy for chest tumors.…”